John B. Hawken

Chief Executive Officer at Immutep SAS

76 year

Consumer Services

Health Technology

Profile

John B.
Hawken is currently the Co-Chief Executive Officer at Immutep SAS since 2010.
Previously, he worked as a Principal at Aptanomics SA. He completed his undergraduate degree at the University of Oxford and holds an MBA from INSEAD.

John B. Hawken active positions

Companies	Position	Start
Immutep SAS Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France.	Chief Executive Officer	2003-12-01

All active positions of John B. Hawken

Former positions of John B. Hawken

Companies	Position	End
Aptanomics SA Aptanomics SA Pharmaceuticals: MajorHealth Technology Aptanomics SA discovers and develops new drugs in major markets of unmet medical need. Its proprietary discovery engine, based on peptide aptamers, delivers a regular flow of new hits against relevant industrial targets. Aptanomics offers opportunities for drug discovery collaborations leveraging the peptide aptamer technology to identify new druggable sites and screen for small molecule hits. The company was founded by Roger Brent, Pierre Colas and Johm B. Hawken in 2001 and is headquarters in Lyon, France	Corporate Officer/Principal	-

See the detail of John B. Hawken's experience

Training of John B. Hawken

University of Oxford	Undergraduate Degree
INSEAD	Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of John B. Hawken's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Immutep SAS Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France.	Health Technology
Aptanomics SA Aptanomics SA Pharmaceuticals: MajorHealth Technology Aptanomics SA discovers and develops new drugs in major markets of unmet medical need. Its proprietary discovery engine, based on peptide aptamers, delivers a regular flow of new hits against relevant industrial targets. Aptanomics offers opportunities for drug discovery collaborations leveraging the peptide aptamer technology to identify new druggable sites and screen for small molecule hits. The company was founded by Roger Brent, Pierre Colas and Johm B. Hawken in 2001 and is headquarters in Lyon, France	Health Technology